Pacira Pharmaceuticals Inc (PCRX)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	638,707	621,403	618,553	613,360	627,091	646,604	609,214	577,203	541,534	491,997	489,092	436,030	429,647	421,097	408,298	435,397	421,026	393,717	372,480	353,983
Receivables	US$ in thousands	105,556	96,956	99,079	93,205	98,397	93,471	91,105	92,103	96,318	49,975	68,357	52,583	53,046	46,143	44,013	38,988	47,530	42,573	41,147	39,766
Receivables turnover		6.05	6.41	6.24	6.58	6.37	6.92	6.69	6.27	5.62	9.84	7.15	8.29	8.10	9.13	9.28	11.17	8.86	9.25	9.05	8.90

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $638,707K ÷ $105,556K
= 6.05

To analyze Pacira BioSciences Inc's receivables turnover, we can calculate the average receivables turnover based on the values provided in the table.

Average Receivables Turnover = (6.39 + 6.87 + 6.75 + 7.18 + 6.78 + 7.00 + 6.74 + 6.30) / 8
Average Receivables Turnover = 6.75

The average receivables turnover for Pacira BioSciences Inc over the past 8 quarters is 6.75. This indicates that, on average, the company is able to convert its accounts receivable into cash approximately 6.75 times within a given period. A higher receivables turnover is generally favorable as it suggests that the company is efficient in collecting payments from its customers.

Analyzing the trend, we see that the receivables turnover has been relatively stable around the average value of 6.75 over the quarters. This consistency may indicate a consistent and effective credit management and collection process within the company.

It is important to consider industry benchmarks and compare Pacira BioSciences Inc's receivables turnover with its peers to gain further insights into the company's performance in managing its accounts receivable.